PDCD1 and colorectal carcinoma: Several clinical studies have investigated low-dose ipilimumab combined with nivolumab in metastatic MSI-H/dMMR CRC, reporting objective response rates of 55-69%, with improved PFS and overall survival (OS) compared to PD-1 inhibitors alone (87, 94).